Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/107605 https://doi.org/10.3389/fchem.2018.00178 |
Resumo: | Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade. |
id |
RCAP_5cc7d72ece47d73e3ad75ee6a4e3eef5 |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/107605 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Highlights in BACE1 Inhibitors for Alzheimer's Disease TreatmentAlzheimer’s Disease (AD)Amyloid-β (Aβ)BACE1inhibitorssmall moleculesdrug discovery and developmentAlzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade.Frontiers Media S.A.2018info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/107605http://hdl.handle.net/10316/107605https://doi.org/10.3389/fchem.2018.00178eng2296-2646Coimbra, Judite R. M.Marques, Daniela F. F.Baptista, Salete J.Pereira, Cláudia FragãoMoreira, Paula I.Dinis, Teresa C. P.Santos, Armanda E.Salvador, Jorge A. R.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T08:35:29Zoai:estudogeral.uc.pt:10316/107605Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:23:56.375013Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
title |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
spellingShingle |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment Coimbra, Judite R. M. Alzheimer’s Disease (AD) Amyloid-β (Aβ) BACE1 inhibitors small molecules drug discovery and development |
title_short |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
title_full |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
title_fullStr |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
title_full_unstemmed |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
title_sort |
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment |
author |
Coimbra, Judite R. M. |
author_facet |
Coimbra, Judite R. M. Marques, Daniela F. F. Baptista, Salete J. Pereira, Cláudia Fragão Moreira, Paula I. Dinis, Teresa C. P. Santos, Armanda E. Salvador, Jorge A. R. |
author_role |
author |
author2 |
Marques, Daniela F. F. Baptista, Salete J. Pereira, Cláudia Fragão Moreira, Paula I. Dinis, Teresa C. P. Santos, Armanda E. Salvador, Jorge A. R. |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Coimbra, Judite R. M. Marques, Daniela F. F. Baptista, Salete J. Pereira, Cláudia Fragão Moreira, Paula I. Dinis, Teresa C. P. Santos, Armanda E. Salvador, Jorge A. R. |
dc.subject.por.fl_str_mv |
Alzheimer’s Disease (AD) Amyloid-β (Aβ) BACE1 inhibitors small molecules drug discovery and development |
topic |
Alzheimer’s Disease (AD) Amyloid-β (Aβ) BACE1 inhibitors small molecules drug discovery and development |
description |
Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/107605 http://hdl.handle.net/10316/107605 https://doi.org/10.3389/fchem.2018.00178 |
url |
http://hdl.handle.net/10316/107605 https://doi.org/10.3389/fchem.2018.00178 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2296-2646 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Frontiers Media S.A. |
publisher.none.fl_str_mv |
Frontiers Media S.A. |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134125222789120 |